HIV patients with high liver enzymes who lost belly fat from tesamorelin were 2.5 times more likely to have normal ALT levels than those who didn't lose fat, even after accounting for other factors.

Scientific Claim

In HIV-infected patients with elevated liver enzymes, tesamorelin responders had a 2.5 times higher odds of ALT normalization compared to nonresponders after adjusting for baseline ALT, clinical trial, and viral hepatitis status.

Original Statement

“The odds of resolution of elevated ALT were 2.5 times higher (OR 95% CI 1.2, 5.3) among responders compared to nonresponders.”

From study:Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV

Evidence Quality Assessment

Claim Status

appropriately stated

Study Design Support

Design supports claim

Appropriate Language Strength

association

Can only show association/correlation

Assessment Explanation

The claim accurately reports the odds ratio with confidence interval without causal language. The study design supports this quantitative association.

Evidence from Studies

Supporting (1)

Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV

Randomized Controlled Trial

Human

2017 Oct 23

Contradicting (0)

No contradicting evidence found

Source Study

Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV

Score: 62

DOI: 10.1097/QAD.0000000000001614

Similar Assertions

HIV patients with high liver enzymes who lost enough belly fat from tesamorelin were more than twice as likely to have their ALT levels return to normal compared to those who didn't lose much fat.

85%

HIV patients with high liver enzymes who lost at least 8% of their visceral fat from the drug were 2.5 times more likely to have their ALT levels return to normal compared to those who didn't lose much fat.

77%

HIV patients with high liver enzymes who lost visceral fat from the drug kept their liver enzyme levels improved for a full year even after stopping the drug and some fat coming back.

75%

For people with HIV and belly fat who have high liver enzyme levels, those who lost at least 8% of their visceral fat from tesamorelin treatment had much bigger drops in their liver enzyme levels compared to those who didn't lose much fat.

73%

HIV patients with high ALT who lost visceral fat had a 35% chance of normalizing their ALT levels after 6 months, compared to 18% who didn't lose fat, showing a clear benefit.

73%